Literature DB >> 29052158

Estimating Health State Utility Values for Comorbidities.

Roberta Ara1, John Brazier2.   

Abstract

A comorbidity is defined as the presence of at least one additional health condition co-occurring with a primary health condition. Decision analytic models in healthcare depict the typical clinical pathway of patients in general clinical practice and frequently include health states defined to represent comorbidities such as sequelae or adverse events. Health state utility values (HSUVs) are often not available for these and analysts generally estimate them. This article provides a summary of the methodological literature on estimating methods frequently used together with worked examples. The three main methods used (minimum, multiplicative and additive) can produce a wide range in the values estimated. In general, the minimum method overestimates observed HSUVs and the magnitude of error tends to increase as the observed values decrease. Conversely, the additive and multiplicative methods generally underestimate observed values and the magnitude of the errors is generally greater for the additive method. HSUVs estimated using the multiplicative method tend to decrease for lower HSUVs and the largest errors are in observed HSUVs >0.6. Differences in estimated values can produce substantial differences in the resulting incremental cost effectiveness ratio. Based on the current evidence, the multiplicative method is advocated but additional research is required to determine appropriate methods when estimating values for additional comorbidities.

Entities:  

Mesh:

Year:  2017        PMID: 29052158     DOI: 10.1007/s40273-017-0551-z

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  7 in total

1.  Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods.

Authors:  Roberta Ara; John Brazier
Journal:  Med Care       Date:  2012-05       Impact factor: 2.983

2.  Predicting utility for joint health states: a general framework and a new nonparametric estimator.

Authors:  Alex Z Fu
Journal:  Med Decis Making       Date:  2010-07-19       Impact factor: 2.583

3.  Populating an economic model with health state utility values: moving toward better practice.

Authors:  Roberta Ara; John E Brazier
Journal:  Value Health       Date:  2010-03-10       Impact factor: 5.725

4.  Estimating health state utility values for comorbid health conditions using SF-6D data.

Authors:  Roberta Ara; John Brazier
Journal:  Value Health       Date:  2011-05-31       Impact factor: 5.725

Review 5.  Estimating health state utility values for joint health conditions: a conceptual review and critique of the current evidence.

Authors:  Roberta Ara; Allan J Wailoo
Journal:  Med Decis Making       Date:  2012-08-27       Impact factor: 2.583

6.  Utilities should not be multiplied: evidence from the preference-based scores in the United States.

Authors:  Alex Z Fu; Michael W Kattan
Journal:  Med Care       Date:  2008-09       Impact factor: 2.983

7.  Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores.

Authors:  William Flanagan; Cameron N McIntosh; Christel Le Petit; Jean-Marie Berthelot
Journal:  Popul Health Metr       Date:  2006-10-31
  7 in total
  6 in total

Review 1.  International Regulations and Recommendations for Utility Data for Health Technology Assessment.

Authors:  Donna Rowen; Ismail Azzabi Zouraq; Helene Chevrou-Severac; Ben van Hout
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

2.  Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation.

Authors:  Hui Shao; Shuang Yang; Vivian Fonseca; Charles Stoecker; Lizheng Shi
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

Review 3.  The Use of Health State Utility Values in Decision Models.

Authors:  Roberta Ara; John Brazier; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

4.  Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA).

Authors:  Marine Lorent; Haïfa Maalmi; Philippe Tessier; Stéphane Supiot; Etienne Dantan; Yohann Foucher
Journal:  BMC Med Inform Decis Mak       Date:  2019-01-07       Impact factor: 2.796

5.  Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting.

Authors:  Tristan M Snowsill; Neil A J Ryan; Emma J Crosbie; Ian M Frayling; D Gareth Evans; Chris J Hyde
Journal:  PLoS One       Date:  2019-08-30       Impact factor: 3.240

6.  Cost-effectiveness of bariatric surgery and non-surgical weight management programmes for adults with severe obesity: a decision analysis model.

Authors:  D Boyers; L Retat; E Jacobsen; A Avenell; P Aveyard; E Corbould; A Jaccard; D Cooper; C Robertson; M Aceves-Martins; B Xu; Z Skea; M de Bruin
Journal:  Int J Obes (Lond)       Date:  2021-06-04       Impact factor: 5.095

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.